Taclonex Suspension

(Betamethasone Dipropionate/Calcipotriol)

Taclonex is used to treat psoriasis, and the mechanism of action works by combining two medicines in one topical product: calcipotriene and betamethasone. Calcipotriene is a vitamin D analog that slows down the overproduction of skin cells, which is a key problem in psoriasis. Betamethasone is a potent corticosteroid that reduces inflammation, redness, itching, and swelling in the affected skin. By both calming inflammation and normalising skin-cell growth, Taclonex helps plaques become thinner, less scaly, and more comfortable.

Follow all directions given to you by your doctor and read all documents provided, including the full Prescribing Information, FDA-Approved Product Labeling, Instructions for Use, and Medication Guide before using Taclonex. However, the following is a synopsis of the general guidelines for the use of Taclonex:

• Taclonex is for topical use only and should not be taken by mouth.
• Apply a thin layer to the affected areas of skin as directed by your healthcare provider.
• Wash your hands before and after application, unless your hands are the area being treated.
• Do not apply Taclonex to the face, groin, axillae, or other sensitive areas unless directed by a healthcare professional.
• Avoid applying to large areas of skin or using more than the prescribed amount.
• Taclonex ointment is typically used once daily on body plaque psoriasis.
• Taclonex topical suspension is commonly used once daily for plaque psoriasis of the scalp.
• Do not cover treated skin with bandages or occlusive dressings unless instructed by your doctor.
• Taclonex may make your skin more sensitive to sunlight. Use sunscreen and wear protective clothing when you are outdoors. Avoid sunlamps and tanning booths.

Some mild or common side effects of Taclonex seen in clinical trials include:

• Skin irritation at the treatment site.
• Burning sensation or itching.
• Dryness or redness of the skin.
• Folliculitis (inflammation of hair follicles).
• Miliaria (stretch marks).

Some individuals may experience serious side effects while using Taclonex. These side effects may require immediate medical attention. If you experience any of the following, contact your healthcare provider or seek emergency medical help:

• Thin skin or skin atrophy.
• Changes in skin color, including hypopigmentation.
• Signs of allergic contact dermatitis, such as severe rash or swelling.
• Symptoms of hypercalcemia or hypercalciuria, including nausea, weakness, or confusion.
• Adrenal gland suppression or signs of Cushing’s syndrome, such as unusual weight gain or fatigue.
• Worsening of skin infection or development of pustular psoriasis.

These are not all of the possible side effects of Taclonex. You should always seek medical advice from your healthcare provider for any questions or concerns about your medical condition or treatment. Read all patient information, medication guides, or drug information sheets that come with this medication. You can also report adverse effects to the Food and Drug Administration at www.fda.gov/medwatch or 1-800-FDA-1088.

Before starting Taclonex, it is crucial to discuss any existing health conditions with your healthcare provider. You should be sure that your healthcare provider is aware of all your medical conditions, including if you have:

• Disorders of calcium metabolism or high calcium levels.
• Liver disease or kidney disease.
• A history of adrenal insufficiency.
• Skin infections at or near the treatment site.
• Glaucoma or cataracts.
• Cushing’s syndrome.
• Hyperglycemia (high blood sugar).

Taclonex should not be used in patients with known hypersensitivity to betamethasone dipropionate, calcipotriene, or any component of the formulation. It is also contraindicated in patients with disorders of calcium metabolism, untreated skin infections, or adverse reactions at the application site.

Many patients notice improvement in redness and scaling within the first week of treatment. More significant improvement in plaque thickness may take several weeks. Full benefits are usually evaluated after the prescribed treatment period, often up to four weeks. Your healthcare provider will assess whether treatment should be continued or adjusted.

When Taclonex is taken with other prescription drugs, over-the-counter medications, vitamins, and supplements, it may change how they work or increase the frequency or severity of side effects. Make sure that you tell your healthcare professional about anything that you are taking to avoid any negative drug interactions, including:

• Other topical corticosteroids may increase the risk of skin atrophy or HPA axis suppression.
• Vitamin D supplements or calcium supplements may increase the risk of elevated calcium levels.
• Other psoriasis treatments applied to the same area may increase irritation or systemic absorption.

Taclonex is available in different dosage forms, including topical ointment and topical suspension. Each formulation contains fixed concentrations of betamethasone dipropionate and calcipotriene. The amount applied depends on the size of the affected skin area and the specific product prescribed.

Taclonex should be stored at room temperature, away from the reach of children or pets.

Taclonex is manufactured by LEO Pharma Inc. Other common brand names include Enstilar and Wynzora.

Yes. Generic name versions containing calcipotriene and betamethasone dipropionate are available.

Do not stop using Taclonex abruptly without consulting your healthcare provider. Sudden discontinuation after prolonged use may worsen psoriasis symptoms. Your healthcare provider may recommend gradually reducing use or switching to another treatment.

Taclonex should be used during pregnancy only if the potential benefit justifies the potential risk to the unborn baby. Use the smallest amount for the shortest duration needed.

Taclonex may pass into breast milk. Do not apply Taclonex to the breast area, and follow your healthcare provider’s advice to reduce potential exposure to the infant.